Hua Medicine
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
275 Ai Di Sheng Road Zhangjiang Hi-tech ...Phone Number
+86 2138101800Website
www.huamedicine.comRevenue
$10.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Hua Medicine
Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders.Explore more
Hua Medicine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hua Medicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Hua Medicine, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Hua Medicine is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Hua Medicine had a recent Job posting/layoffs
Product Launch: Get notified when Hua Medicine launches new products
Earning: See what the market has to say on Hua Medicine recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Hua Medicine
Check if Hua Medicine has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Hua Medicine has new funding data
Recommended Actions
Find VP level buyers at Hua Medicine
Find 3 more new buyers
Company Profile Activity
Activity Insights
Hua Medicine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hua Medicine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hua Medicine.
Hua Medicine financials insights
Gather financial insights about Hua Medicine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$50M
2015
Series B
$25M
2016
Series C
$50M
Hua Medicine Tech Stack
A closer look at the technologies used by Hua Medicine
Most Recent Scoops
Person-Based
Earnings, Finance, Investor Relations
Person-Based
Research & Development, Pharmaceuticals, Clinical Operations
Person-Based
Person-Based
Person-Based
Hua Medicine News & Media
Hua Medicine Advances Glucose Homeostasis Platform at ADA 2026, Showcasing Dorzagliatin's Potential Across Metabolic Disease
SHANGHAI, Jun 9, 2026 - (ACN Newswire) - Hua Medicine ("the Company", stock code: 2552.HK) presented a series of breakthrough research findings on dorzagliatin (Trade name: HuaTangNing, Trade name in Hong Kong: MYHOMSIS(R)), the world’s first-in-class glucokinase activator (GKA), at the 86th Scientific Sessions of the American Diabetes Association (ADA). Through oral and poster presentations that demonstrated the breadth and depth of its science, the Company showcased data from its Metabolic HomHua Medicine (Shanghai) Ltd. (HUMDF) Q4 2025 Earnings Call Transcript
Hua Medicine (Shanghai) Ltd. (HUMDF) Q4 2025 Earnings Call March 26, 2026 10:30 PM EDTCompany ParticipantsChen Li - Founder, CEO & Executive...Hua Medicine Announces 2025 Annual Results
- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation. - Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growtHua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to Type 2 diabetes (T2D) management Hong Kong will serve as Hua Medicine's launchpad for international market expansion SHANGHAI and HONG KONG, March 3, 2026 /PRNewswire/ -- Hua...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hua Medicine
Sign Up For FreeTo access detailed company insights
Hua Medicine is a leading clinical-stage, innovative drug development company in China, focusing on novel therapies for the treatment of diabetes and CNS disorders.... Read More
